12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vargatef nintedanib: Phase I data

A dose-escalation Phase I trial in 45 patients with advanced solid tumors showed that 10-40 mg afatinib given daily on a continuous or intermittent schedule (every other week) in combination with twice-daily 150 mg nintedanib in a 28-day cycle led to 2 partial responses and 27 cases of...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >